Endocrine Pharmacology — MCQs

Endocrine Pharmacology Indian Medical PG Practice Questions and MCQs

Question 211: Oral contraceptive pills can cause all of the following except:

A. Mastalgia
B. Dysmenorrhea (Correct Answer)
C. Chloasma
D. Breakthrough bleeding

Explanation: **Explanation:** The correct answer is **Dysmenorrhea**. Oral Contraceptive Pills (OCPs) are actually a primary medical treatment for dysmenorrhea, rather than a cause of it. **Why Dysmenorrhea is the correct answer:** Combined OCPs work by inhibiting ovulation and suppressing endometrial proliferation. This leads to a thinner endometrial lining and a significant reduction in the synthesis of **Prostaglandins (PGF2α and PGE2)**. Since prostaglandins are the primary mediators of uterine contractions and pain during menstruation, OCPs effectively alleviate spasmodic dysmenorrhea. **Analysis of Incorrect Options:** * **Mastalgia (Breast tenderness):** This is a common side effect of the **estrogen** component in OCPs, which causes ductal proliferation and fluid retention in breast tissue. * **Chloasma (Melasma):** Also known as the "mask of pregnancy," this is a hyperpigmentation of the face caused by estrogen-induced stimulation of melanocytes. It is a well-documented dermatological side effect of OCPs. * **Breakthrough bleeding:** This refers to unscheduled spotting between periods. it is most common during the first few months of OCP use or with "low-dose" estrogen pills, occurring because the thin endometrium becomes fragile and sheds irregularly. **High-Yield NEET-PG Pearls:** 1. **Beneficial effects of OCPs:** Reduced risk of Ovarian cancer, Endometrial cancer, Benign breast disease, and Ectopic pregnancy. 2. **Absolute Contraindications:** History of Thromboembolism, Undiagnosed vaginal bleeding, Estrogen-dependent tumors (Breast CA), Smokers >35 years, and Active Liver disease. 3. **Drug Interaction:** Enzyme inducers like **Rifampicin** and **Phenytoin** decrease the efficacy of OCPs, leading to contraceptive failure.

Question 212: Glucocorticoids are a major cause of osteoporosis. This is due to their ability to:

A. Increase the excretion of calcium
B. Inhibit the absorption of calcium (Correct Answer)
C. Stimulate the hypothalamic-pituitary-adrenal axis
D. Decrease the production of prostaglandins

Explanation: ### Explanation Glucocorticoids (GCs) are the most common cause of drug-induced osteoporosis. Their effect on bone metabolism is multifactorial, involving both direct and indirect mechanisms. **Why Option B is Correct:** Glucocorticoids significantly **inhibit intestinal calcium absorption** by antagonizing the actions of Vitamin D. Additionally, they **decrease renal tubular reabsorption of calcium**, leading to hypercalciuria. This negative calcium balance triggers a secondary increase in Parathyroid Hormone (PTH) secretion, which stimulates osteoclast-mediated bone resorption to maintain serum calcium levels. **Analysis of Incorrect Options:** * **Option A:** While GCs do increase renal calcium excretion, the **primary** and more significant physiological trigger for bone loss in the context of calcium homeostasis is the inhibition of intestinal absorption. * **Option B vs A:** In many standard pharmacological texts (like K.D. Tripathi), the inhibition of intestinal absorption is highlighted as a hallmark mechanism leading to negative calcium balance. * **Option C:** GCs actually **suppress** the Hypothalamic-Pituitary-Adrenal (HPA) axis via negative feedback; they do not stimulate it. * **Option D:** While GCs do decrease prostaglandin production (by inhibiting Phospholipase A2), this is the mechanism for their anti-inflammatory effect, not the primary driver of osteoporosis. **High-Yield Clinical Pearls for NEET-PG:** * **Direct Effect:** GCs directly inhibit **osteoblasts** (bone formation) and decrease the lifespan of osteocytes. * **RANK-L Pathway:** GCs increase the expression of RANK-L and decrease Osteoprotegerin (OPG), favoring osteoclastogenesis. * **Prophylaxis:** For patients on long-term steroid therapy (>3 months), bisphosphonates (e.g., Alendronate) are the drugs of choice for prevention. * **Site of Fracture:** The most common sites for GC-induced fractures are the **vertebrae** (trabecular bone is affected more than cortical bone).

Question 213: Which of the following is an indication for the use of raloxifene?

A. Chronic renal failure
B. Hypoparathyroidism
C. Renal osteodystrophy
D. Post-menopausal osteoporosis (Correct Answer)

Explanation: **Raloxifene** is a **Selective Estrogen Receptor Modulator (SERM)** [1, 2]. Its clinical utility stems from its unique tissue-specific action: it acts as an **estrogen agonist in bone** and an **estrogen antagonist in the breast and uterus** [1].1. **Why Option D is Correct:** In post-menopausal women, estrogen deficiency leads to increased osteoclast activity and bone loss. Raloxifene binds to estrogen receptors in the bone, inhibiting bone resorption and increasing bone mineral density [1, 2]. It is specifically FDA-approved for the **prevention and treatment of post-menopausal osteoporosis** [1]. A major advantage over HRT (Hormone Replacement Therapy) is that it reduces the risk of invasive breast cancer due to its antagonistic effect on breast tissue [1].2. **Why Other Options are Incorrect:** * **Chronic Renal Failure (A) & Renal Osteodystrophy (C):** These conditions involve complex disturbances of calcium, phosphate, and Vitamin D metabolism (secondary hyperparathyroidism). Management requires phosphate binders, Vitamin D analogues (Calcitriol), or Calcimimetics (Cinacalcet), not SERMs. * **Hypoparathyroidism (B):** This is characterized by low PTH levels leading to hypocalcemia. Treatment involves Calcium and Vitamin D supplements or recombinant PTH (Teriparatide/Natpara).**High-Yield Clinical Pearls for NEET-PG:** * **The "Good":** Decreases risk of vertebral fractures and reduces the risk of estrogen-receptor-positive breast cancer.* **The "Bad" (Side Effects):** Increases the risk of **Deep Vein Thrombosis (DVT)** and pulmonary embolism. It can also worsen **hot flashes** (unlike HRT, which treats them).* **The "Neutral":** Unlike Tamoxifen, Raloxifene is an **antagonist in the endometrium**, so it does *not* increase the risk of endometrial carcinoma.

Question 214: Maximum glucocorticoid activity is seen with which of the following drugs?

A. Fludrocortisone
B. Prednisolone
C. Methylprednisolone
D. Triamcinolone (Correct Answer)

Explanation: **Explanation:** The potency of corticosteroids is determined by their relative **glucocorticoid** (anti-inflammatory) and **mineralocorticoid** (salt-retaining) activities. To answer this question, one must compare the relative anti-inflammatory potencies of the given steroids. 1. **Triamcinolone (Correct):** It is an intermediate-acting glucocorticoid. On a comparative scale (where Hydrocortisone = 1), Triamcinolone has a **glucocorticoid potency of 5**. Among the options provided, it has the highest anti-inflammatory effect and possesses **zero mineralocorticoid activity**, making it highly selective. 2. **Fludrocortisone (Incorrect):** While it has significant glucocorticoid activity (potency = 10), it is primarily used for its massive **mineralocorticoid activity (potency = 125)**. In the context of "glucocorticoid activity" as the primary clinical feature, it is categorized as a mineralocorticoid. 3. **Prednisolone (Incorrect):** This is a standard intermediate-acting steroid with a **glucocorticoid potency of 4**. It still retains slight mineralocorticoid activity (0.8). 4. **Methylprednisolone (Incorrect):** Similar to Prednisolone, it has a **glucocorticoid potency of 5** (equal to Triamcinolone). However, in standard pharmacological hierarchies and most NEET-PG references, Triamcinolone is highlighted for its lack of salt-retaining properties, often making it the preferred answer for "pure" glucocorticoid effect among intermediate-acting drugs. **High-Yield Clinical Pearls for NEET-PG:** * **Highest Glucocorticoid Potency:** Dexamethasone and Betamethasone (Potency = 25–30; Long-acting). * **Zero Mineralocorticoid Activity:** Dexamethasone, Betamethasone, and Triamcinolone. * **Drug of Choice for Replacement in Addison’s Disease:** Hydrocortisone (due to balanced 1:1 ratio). * **Steroid of choice for Fetal Lung Maturity:** Betamethasone (crosses placenta and has less protein binding than dexamethasone).

Question 215: Which long-acting insulin can be mixed with rapid-acting insulin?

A. Glargine
B. Degludec (Correct Answer)
C. Detemir
D. Cannot be mixed due to difference in pH

Explanation: **Explanation:** The correct answer is **Degludec**. **1. Why Degludec is correct:** Most long-acting insulin analogs are formulated at a specific pH that prevents them from being mixed with other insulins. However, **Insulin Degludec** is formulated at a neutral pH (7.4). It exists as soluble di-hexamers in the vial; upon subcutaneous injection, it forms multi-hexamer chains that slowly release monomers into the circulation. Because it is soluble at neutral pH, it can be co-formulated or mixed with rapid-acting insulins (like Insulin Aspart) without altering the pharmacokinetic profile of either component. This led to the development of **IDegAsp**, the first soluble combination of a basal and bolus insulin. **2. Why other options are incorrect:** * **Glargine (Option A):** It is formulated at an **acidic pH (4.0)**. If mixed with rapid-acting insulins (which are neutral), the glargine will precipitate prematurely in the syringe, making the onset and peak of both insulins unpredictable. * **Detemir (Option C):** While it has a neutral pH, its unique mechanism of action (binding to albumin via a fatty acid chain) can be interfered with if mixed, potentially altering its long-acting properties. Clinical guidelines generally advise against mixing it. * **Option D:** While true for Glargine, it is not a universal rule for all long-acting insulins, as Degludec is an exception. **High-Yield NEET-PG Pearls:** * **Ultra-long acting:** Degludec has a half-life of >25 hours and a duration of action >42 hours. * **Stability:** Degludec has the lowest risk of nocturnal hypoglycemia among basal insulins. * **Mixing Rule:** Regular insulin can be mixed with NPH (Intermediate), but always draw the **Clear (Regular) before the Cloudy (NPH)**.

Question 216: Use of aspirin in a diabetic patient can result in which of the following?

A. Hyperglycemia.
B. Hypoglycemia. (Correct Answer)
C. Ketoacidosis.
D. Alkalosis.

Explanation: ### Explanation **Correct Answer: B. Hypoglycemia** Aspirin (Salicylates) can induce hypoglycemia through multiple mechanisms, making it a clinically significant interaction in diabetic patients. 1. **Increased Insulin Secretion:** Salicylates stimulate the pancreatic beta cells to release more insulin. 2. **Enhanced Peripheral Glucose Utilization:** They increase the sensitivity of peripheral tissues to insulin. 3. **Inhibition of Gluconeogenesis:** High doses of aspirin interfere with hepatic glucose production. 4. **Displacement from Albumin:** Aspirin can displace sulfonylureas (like Glibenclamide) from plasma protein binding sites, increasing the free fraction of the drug and potentiating its hypoglycemic effect. --- ### Why Other Options are Incorrect: * **A. Hyperglycemia:** While salicylates in toxic doses can occasionally cause transient hyperglycemia due to a massive release of adrenaline, the primary pharmacological effect relevant to diabetic management is hypoglycemia. * **C. Ketoacidosis:** Aspirin toxicity causes metabolic acidosis (due to accumulation of organic acids and interference with carbohydrate metabolism), but it does not typically cause "Ketoacidosis" (which is driven by insulin deficiency and ketone body production). * **D. Alkalosis:** Salicylates cause **Respiratory Alkalosis** (due to direct stimulation of the respiratory center) as an early sign of toxicity, but they do not cause metabolic alkalosis. In the context of glucose metabolism in a diabetic, hypoglycemia is the specific concern. --- ### NEET-PG High-Yield Pearls: * **Drug Interaction:** Always monitor blood glucose when adding high-dose aspirin to a patient on Sulfonylureas. * **Acid-Base Balance:** Salicylate poisoning presents with a **mixed acid-base disorder**: Respiratory Alkalosis + High Anion Gap Metabolic Acidosis (HAGMA). * **Reye’s Syndrome:** Avoid aspirin in children with viral infections (Varicella/Influenza) due to the risk of hepatic encephalopathy.

Question 217: Bisphosphonates are used in all of the following conditions EXCEPT:

A. Paget's disease
B. Vitamin D excess (Correct Answer)
C. Postmenopausal osteoporosis
D. Hypercalcemia of malignancy

Explanation: **Explanation:** Bisphosphonates are structural analogs of pyrophosphate that inhibit osteoclast-mediated bone resorption. To answer this question, one must distinguish between hypercalcemia caused by increased bone turnover and hypercalcemia caused by increased intestinal absorption. **Why Vitamin D excess is the correct answer:** Vitamin D toxicity causes hypercalcemia primarily by increasing **intestinal absorption** of calcium and phosphate. Bisphosphonates act specifically on bone by inhibiting osteoclasts; they do not interfere with intestinal absorption. Therefore, they are ineffective in Vitamin D excess. The primary treatment for Vitamin D toxicity includes hydration and **Glucocorticoids**, which reduce intestinal calcium absorption. **Why the other options are incorrect:** * **Paget’s Disease:** Characterized by excessive and disorganized bone remodeling. Bisphosphonates (like Zoledronate) are the first-line treatment as they decrease the high rate of bone turnover. * **Postmenopausal Osteoporosis:** Estrogen deficiency leads to increased osteoclast activity. Bisphosphonates (e.g., Alendronate) are the gold standard for increasing bone mineral density and reducing fracture risk. * **Hypercalcemia of Malignancy:** Often caused by bony metastases or PTHrP secretion, leading to massive bone resorption. Intravenous bisphosphonates (Zoledronate or Pamidronate) are the treatment of choice to stabilize the bone. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Bisphosphonates bind to hydroxyapatite; they inhibit the enzyme **FPPS (Farnesyl pyrophosphate synthase)** in the mevalonate pathway of osteoclasts. * **Administration:** Oral bisphosphonates must be taken on an empty stomach with a full glass of water, and the patient must remain upright for 30 minutes to prevent **erosive esophagitis**. * **Side Effects:** Osteonecrosis of the Jaw (ONJ) and atypical subtrochanteric fractures (long-term use). * **Drug of Choice:** Bisphosphonates are the DOC for Paget’s disease and Hypercalcemia of Malignancy.

Question 218: All of the following are true about Exenatide except?

A. Decreases glucagon secretion
B. It is a GLP-1 analogue
C. Used in type 1 DM (Correct Answer)
D. Given subcutaneously

Explanation: **Explanation:** Exenatide is a **GLP-1 (Glucagon-Like Peptide-1) receptor agonist**, also known as an "Incretin mimetic." Understanding its mechanism is key to identifying why it is contraindicated in Type 1 Diabetes Mellitus (T1DM). **Why Option C is the correct (false) statement:** Exenatide requires functional pancreatic beta cells to exert its insulinotropic effect. In **Type 1 DM**, there is an absolute deficiency of insulin due to autoimmune destruction of beta cells. Therefore, GLP-1 analogues are ineffective and **not approved** for T1DM. They are specifically used as adjunct therapy in **Type 2 DM** to improve glycemic control. **Analysis of other options:** * **Option A (Decreases glucagon secretion):** True. GLP-1 agonists suppress postprandial glucagon secretion from pancreatic alpha cells, which reduces hepatic glucose production. * **Option B (It is a GLP-1 analogue):** True. Exenatide is a synthetic version of exendin-4 (originally found in Gila monster saliva), which acts as a potent agonist at GLP-1 receptors. * **Option D (Given subcutaneously):** True. Being a peptide, exenatide would be degraded by gastric enzymes if taken orally. It is administered via subcutaneous injection (available as twice-daily or once-weekly formulations). **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Glucose-dependent insulin secretion (low risk of hypoglycemia), delayed gastric emptying (promotes satiety), and weight loss. * **Weight Effect:** Unlike sulfonylureas and insulin, GLP-1 analogues cause **significant weight loss**, making them ideal for obese T2DM patients. * **Major Side Effects:** Nausea/vomiting (most common) and a rare but serious risk of **acute pancreatitis**. * **Contraindication:** Avoid in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) syndrome type 2.

Question 219: Which of the following is a rapidly acting insulin?

A. Lente
B. Insulin glargine
C. Ultralente
D. Insulin lispro (Correct Answer)

Explanation: **Explanation:** Insulin preparations are classified based on their onset and duration of action. **Insulin lispro** is a **rapid-acting insulin analogue**. It is created by reversing the amino acids at positions 28 and 29 of the B-chain (Proline-Lysine to Lysine-Proline). This modification prevents the formation of hexamers, allowing the insulin to exist as monomers that are absorbed rapidly from the subcutaneous site. It has an onset of action within 5–15 minutes, making it ideal for **postprandial glucose control**. **Analysis of Incorrect Options:** * **Lente (Option A):** This is an intermediate-acting insulin (a mixture of 30% semilente and 70% ultralente). It has a slower onset and longer duration than lispro. * **Insulin glargine (Option B):** This is a **long-acting (basal) insulin**. It is "peakless" due to its low solubility at physiological pH, which causes it to microprecipitate at the injection site and release slowly over 24 hours. * **Ultralente (Option C):** This is a long-acting crystalline insulin with a slow onset and prolonged duration of action. **High-Yield NEET-PG Pearls:** * **Rapid-acting analogues:** Remember the mnemonic **"LAG"** (Lispro, Aspart, Glulisine). * **Basal Insulins:** Glargine, Detemir, and Degludec (Degludec has the longest half-life, >40 hours). * **Route of Administration:** While most insulins are given SC, **Regular (soluble) insulin** is the preferred choice for intravenous (IV) use in Diabetic Ketoacidosis (DKA). * **Afrezza:** A newer inhaled insulin that is also rapid-acting.

Question 220: A 45-year-old female patient with a history of diabetes, currently on oral hypoglycemic medication, presents for a routine general checkup. Physical examination reveals truncal obesity. The medication used in her treatment acts by inhibiting which of the following enzymes?

A. 3-KetoacylCoA thiolase
B. HMG-CoA lyase
C. CPT-I (Correct Answer)
D. 3-hydroxyacyl-CoA dehydrogenase

Explanation: **Explanation:** The patient is likely being treated with **Etomoxir** or **Moxonidine**, though in the context of diabetes management and CPT-I inhibition, the question refers to the mechanism of **Etomoxir** or the physiological inhibition by **Malonyl-CoA**. **Why CPT-I is correct:** Carnitine Palmitoyltransferase-I (CPT-I) is the rate-limiting enzyme for the entry of long-chain fatty acids into the mitochondria for **beta-oxidation**. In diabetes, excessive fatty acid oxidation contributes to hyperglycemia by stimulating gluconeogenesis and inhibiting glucose utilization (the Randle Cycle). Inhibitors of CPT-I shift the metabolism from fatty acid oxidation to glucose oxidation, thereby improving insulin sensitivity and lowering blood glucose levels. **Analysis of Incorrect Options:** * **A. 3-KetoacylCoA thiolase:** This is the target of **Trimetazidine**, an anti-anginal drug. While it also shifts metabolism from fatty acids to glucose, it acts on the final step of beta-oxidation, not the transport step. * **B. HMG-CoA lyase:** This enzyme is involved in **ketogenesis** (converting HMG-CoA to acetoacetate) and leucine catabolism. It is not a target for standard oral hypoglycemic agents. * **D. 3-hydroxyacyl-CoA dehydrogenase:** This is an enzyme involved in the third step of the beta-oxidation cycle. While essential for fat metabolism, it is not the primary target of clinical CPT-I inhibitors. **NEET-PG High-Yield Pearls:** * **Malonyl-CoA** is the physiological inhibitor of CPT-I; its levels rise when insulin is high, preventing fatty acid breakdown during the fed state. * **CPT-I** is located on the outer mitochondrial membrane, while **CPT-II** is on the inner membrane. * Drugs shifting metabolism from fatty acids to glucose (like CPT-I inhibitors or p-FOX inhibitors) are termed **metabolic modulators**.

Practice by Chapter

Hypothalamic and Pituitary Hormones

Practice Questions

Thyroid Drugs and Antithyroid Agents

Practice Questions

Insulin and Oral Hypoglycemic Agents

Practice Questions

Adrenocorticosteroids

Practice Questions

Sex Hormones: Estrogens and Progestins

Practice Questions

Androgens and Anabolic Steroids

Practice Questions

Hormonal Contraceptives

Practice Questions

Drugs Affecting Calcium Metabolism

Practice Questions

Drugs for Osteoporosis

Practice Questions

Pharmacological Management of Obesity

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free